Madrigal Pharmaceuticals, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Madrigal Pharmaceuticals will hold its annual stockholders meeting on June 20, 2025, to vote on director re-elections, auditor ratification, executive compensation, and other business.
NASDAQ
DEF 14A: Madrigal Pharmaceuticals' Proxy Statement Reveals Landmark Year Following Rezdiffra Approval
Madrigal Pharmaceuticals' proxy statement highlights a transformational 2024, marked by the FDA approval and successful launch of Rezdiffra, the first-ever medicine for MASH.
NASDAQ
Madrigal Pharmaceuticals will hold its annual stockholders meeting on June 25, 2024, to vote on director re-elections, auditor ratification, executive compensation, and a stock plan amendment.
NASDAQ
DEF 14A: Madrigal Pharmaceuticals Achieves Landmark Approval for NASH Treatment and Outlines Future Strategy
Madrigal Pharmaceuticals highlights a transformational year marked by the FDA approval of Rezdiffra, significant financial milestones, and strategic leadership changes.